## Form H - entering CDI hospital-based data

Follow the procedure in this section to create a new CDI survey for each defined hospital, entering information from Form H. Before you can create your survey, you must define your hospital and wards.

To create a CDI hospital survey:

1. Click Hospital surveillance periods in the CDI main menu.

The Hospital survey form opens for the hospital you have selected.

2. If not already open, click the Form H tab.

3. In the Form H form, click the Add item icon to open the form for editing.

The data entered here is hospital data applicable to the Minimal, Light and Enhanced surveillance options.

4. Specify the values for the fields.

Descriptions of the variables in Form H are given in Table 7. Mandatory fields are indicated by a red asterisk *. Required fields are indicated by a black asterisk *.

5. Click the Save icon or press Ctrl+S.

If any mandatory or required data field is empty when you save, e.g. because you do not yet have the data, an error and/or warning message is shown and the field label is highlighted as a reminder - in red for a mandatory field (you cannot save) or blue for a required field. See Understanding reported errors.

6. Click Select this hospital surveillance period to return to the main menu and proceed to enter Form C data.

You can now see the surveillance period in the List of periods tab (click Refresh).

Table 7: CDI Form H variables

Variable | Description
Hospital code * | The hospital identifier/code assigned by the national/regional CDI surveillance coordinator. Hospital codes should be unique within each surveillance network, and kept constant between the ECDC Antimicrobial Resistance and Healthcare-Associated Infection (ARHAI) surveillance protocols and from one year to the next. Inserted automatically based on the hospital selected during Hospital definition.
CDI Surveillance option * | Specify the CDI surveillance option to be used. You can select either Minimal, Light or Enhanced. Note that you can later change from Minimal to Light, or from Light to Enhanced, but not vice versa. Refer to the CDI Protocol for detailed descriptions of the three options.
Surveillance period from * | The start date of the survey. You can have multiple surveys, but two surveys cannot start on the same date. Warning: You cannot change the Surveillance period from date after you have saved it. If you save without having selected the correct date, today’s date is applied by default. Before saving, make sure that the start date of the hospital CDI survey is earlier than any ward survey date. If you need to change the start date, you will have to contact your national or regional CDI co-ordinator.
To | The end date of the survey. Can be entered at a later time and can also later be changed.
Hospital type * | Designate the hospital type – PRIM: primary, SEC: secondary, TERT: tertiary, SPEC: specialised, missing=UNK. See Hospital types.
Specialisation of hospital | Free text. Indicate the hospital specialty for a specialised hospital (e.g. paediatric, infectious diseases, etc.); please use specialty codes if possible.
Exclusion of wards | All wards should be included for the surveillance of CDI, exclusion of wards is strongly discouraged. If, despite this recommendation, certain wards were excluded, it is crucial that the aggregated denominator data are provided for the included wards only.
If yes, specify wards | Free text field. Enter the name or ID of any ward excluded from the survey. Max. 100 characters.
Hospital size (total number of beds) * | Number of hospital beds for the current surveillance period. If, despite the recommendation to the contrary, certain wards were excluded, it is crucial that the aggregated denominator data are provided for the included wards only.
Number of discharges (or admissions) * | Number of hospital discharges in the current surveillance period. Use number of admissions if discharges are not available.
Number of patient-days * | Number of hospital patient-days in the current surveillance period.
Number of HA CDI cases * | Number of healthcare-associated CDI cases within the surveillance period (i.e. with onset on day three or later, following admission to a healthcare facility on day one, OR in the community within four weeks of discharge from any healthcare facility). Exclude recurrent cases.
Number of CA CDI cases or CDI cases of unknown origin * | Number of community-associated CDI cases and cases of unknown origin within the surveillance period i.e. onset outside of healthcare facilities, AND without discharge from a healthcare facility within the previous 12 weeks, OR onset on the day of admission to a healthcare facility or on the following day AND not resident in a healthcare facility within the previous 12 weeks, OR a CDI case discharged from a healthcare facility 4–12 weeks before the onset. Exclude recurrent cases.
Number of recurrent CDI cases * | Number of CDI episodes with onset within two and eight weeks of a previous episode (including both healthcare-associated and community-associated recurrent cases).
Number of stool specimens tested * | Number of stool specimens tested for CDI in the surveillance period. Each specimen should only be counted once, even if more than one test was performed on that specimen.
Number of stool specimens that tested positive for CDI * | Number of stools tested for CDI with a positive test result in the surveillance period. Each specimen should only be counted once.
Algorithm used for CDI diagnosis | The laboratory test(s) applied on faeces samples to recognise the presence of toxin-producing C. difficile, either as a solitary test or as a combination of screening and confirmatory tests. If multiple algorithms are applied (i.e. depending on work hours or patient categories), please indicate the most frequently applied algorithm(s), that is/are used for more than 80% of the samples tested for C. difficile. • Toxin A/B EIA Enzyme immunoassays, including enzyme-linked immunosorbent assays (ELISA), that test for both toxins A and B in stool samples or cultures. • GDH EIA Enzyme immunoassays, including enzyme-linked immunosorbent assays (ELISA), that test for both Glutamate dehydrogenase in stool samples or cultures. • NAAT Nucleic acid amplification tests. • Cytotoxicity assay Demonstration that stool sample supernatant kills a cell monolayer in the absence of a C. difficile toxin-neutralising antibody. • Toxigenic culture Demonstration that a C. difficile culture is able to produce toxins in vitro, e.g. by cytotoxicity assays, Toxin A/B EIA or NAAT from colonies. • Toxin detection Detection of toxins, in stool samples or cultures, e.g. by toxin A/B EIA or cell cytotoxicity assays.
Specify algorithm, if other | Free text field. If none of the listed algorithms matches your algorithm, indicate the algorithm which matches most closely. Max. 255 characters.

More:

Surveillance period User tab

HelicsWin.Net v2.2 Online User Guide v20160330
© European Centre for Disease Prevention and Control, 2016
Reproduction is authorised, provided the source is acknowledged